Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 2/20 | 0.30 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3183887 | 0.92 | MEN1 (0.36) | MEN1GAAKMT2AITGA4ITGB7 | |
| SCHEMBL3657314 | 0.87 | CA12 (0.35) | MEN1GAAKMT2AITGA4ITGB7 | |
| SCHEMBL2139561 | 0.83 | MEN1 (0.39) | MEN1GAAKMT2AITGA4ITGB7 | |
| SCHEMBL9955219 | 0.83 | — | — | |
| SCHEMBL2139570 | 0.79 | CA12 (0.37) | MEN1GAAKMT2AITGA4ITGB7 | |
| SCHEMBL6901600 | 0.79 | CA12 (0.37) | MEN1GAAKMT2AITGA4ITGB7 | |
| SCHEMBL68202 | 0.78 | CA1 (0.35) | MEN1GAAKMT2AITGA4ITGB7 | |
| SCHEMBL7898636 | 0.76 | CTSK (0.42) | MEN1GAAKMT2AITGA4ITGB7 | |
| SCHEMBL2137962 | 0.76 | CTSK (0.42) | MEN1GAAKMT2AITGA4ITGB7 | |
| SCHEMBL1583222 | 0.76 | KMT2A (0.38) | MEN1GAAKMT2AITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509502-B2 | Hybrid immunoglobulin containing nonpeptidyl linkage | BIOMOLECULAR HOLDINGS LLC (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250270163-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | REGENERON PHARMA (US) | 2025-08-28 | — | — | US | disclosed |
| US-12338199-B2 | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| CN-118384290-A | Hybrid immunoglobulins containing non-peptide linkages | 生物分子控股有限责任公司 | 2024-07-26 | — | — | CN | disclosed |
| WO-2024100552-A1 | PRODRUGS AND COMPOSITIONS FOR OPHTHALMOLOGY APPLICATIONS | ALCON INC. (CH) | 2024-05-16 | — | — | WO | disclosed |
| EP-4169944-A1 | PROCESS FOR PREPARING HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | Biomolecular Holdings LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220275108-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC (US) | 2022-09-01 | — | — | US | disclosed |
| EP-4039281-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | Biomolecular Holdings LLC (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-3701971-B1 | COMPOUNDS USEFUL IN PREPARING HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220112158-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2022-04-14 | — | — | US | disclosed |
| WO-2004035576-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004021996-A2 | BACKBONE-SUBSTITUTED BIFUNCTIONAL DOTA LIGANDS, COMPLEXES AND COMPOSITIONS THEREOF, AND METHODS OF USING SAME | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2004-03-18 | — | — | WO | disclosed |
| CN-1434822-A | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER AG (DE) | 2003-08-06 | — | — | CN | disclosed |
| US-20020048774-A1 | Liquid phase parallel synthesis of chemical libraries | BRISTOL-MYERS SQUIBB PHARMA RESEARCH LABS, INC. | 2002-04-25 | — | — | US | disclosed |
| US-6245937-B1 | COMBINATORIAL LIBRARIES OF CHEMICAL COMPOUNDS SYNTHESIZED BY BIPHASIC SYNTHESIS UTILIZING SPECIFIED TEMPLATES | DUPONT PHARMACEUTICALS RESEARCH LABORATORIES, INC. | 2001-06-12 | — | — | US | disclosed |
| WO-2000059896-A1 | 225Ac-HEHA AND RELATED COMPOUNDS, METHODS OF SYNTHESIS AND METHODS OF USE | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-0503301-B1 | Peptide derivatives and application thereof | FUJI PHOTO FILM CO LTD (JP) | 1997-11-26 | — | — | EP | disclosed |
| US-5436221-A | Oligopeptides as antitumor agents | FUJI PHOTO FILM CO., LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0619118-A1 | Use of peptide derivatives | FUJI PHOTO FILM CO., LTD. (JP) | 1994-10-12 | — | — | EP | disclosed |
| EP-0503301-A2 | Peptide derivatives and application thereof | FUJI PHOTO FILM CO., LTD. (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275108-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | FCGR3B, FCGR2A, VSIG8 | MEN1 4505/4885GAA 4742/4885KMT2A 2199/4885 |
| US-12338199-B2 | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | NR1H4, NR1H3, OGFR | MEN1 4763/4885GAA 2178/4885KMT2A 2525/4885 |
| US-20020048774-A1 | Liquid phase parallel synthesis of chemical libraries | CDK2, CDC25C, POLR2H | MEN1 3009/4885GAA 4044/4885KMT2A 1893/4885 |
| US-20220112158-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | NR1H4, NR1H3, OGFR | MEN1 4763/4885GAA 2178/4885KMT2A 2525/4885 |
| US-20250270163-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | NR1H4, NR1H3, OGFR | MEN1 4763/4885GAA 2178/4885KMT2A 2525/4885 |
| US-12509502-B2 | Hybrid immunoglobulin containing nonpeptidyl linkage | FCGR2A, FCGR3B, CD74 | MEN1 3731/4885GAA 4768/4885KMT2A 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.